c
x
chart
exchange
Terminal
Flow
Screener
Markets
Trends
Premium
Alerts
EST
UTC-5 New York
Blue Chip
Log in
Sign up
Niagen Bioscience outlines plans for 5,000-participant, 3-year Mass General Brigham trial as it targets early 2027 NR malate commercialization
Seeking Alpha | Nov 5, 2026 1:45 AM EST
Read original article